博文

抗新型冠状病毒新药瑞德西韦(Remdesivir,GS-5734)简介及近年相关研发情况

已有 11824 次阅读 2020-2-8 16:54 |系统分类:论文交流

Remdesivir（瑞德西韦,GS-5734）是吉利德科学在研药品,主要是真对非典型性肺炎（SARS）和中东呼吸综合征（MERS）包括埃博拉病毒感染等研发的药物，在新型冠状病毒疫情抗击中，发现可能存在较强抗新型冠状病毒作用，目前已经进入临床三期实验，对危重病病毒感染者进行临床实验。

据悉，吉利德已与中国卫生部门达成了协议，支持对2019-nCoV感染者开展两项临床试验，以确定瑞德西韦作为冠状病毒潜在治疗手段的安全性和有效性。其中一项研究评估瑞德西韦用于确诊感染2019-nCoV且已住院但未表现出显著临床症状（如需要额外吸氧）的患者的治疗效果，另一项研究则评估瑞德西韦用于出现较严重临床症状（如需要吸氧）的确诊病患的疗效。

药物基本数据：

Remdesivir 是一种核苷类似物，具有抗病毒活性，在 HAE 细胞中，对 SARS-CoV 和 MERS-CoV 的 EC50 值为 74 nM，在延迟脑肿瘤细胞中，对鼠肝炎病毒的 EC50 值为 30 nM。

中文名称：瑞德西韦

英文名称：Remdesivir

CAS：NO.1809249-37-3

分子式：C27H35N6O8P

分子量：602.576

分子结构：

用途

全球临床试验数据库显示，吉利德在研药Remdesivir（瑞德西韦）治疗新型冠状病毒的临床试验将于2月3日在北京中日友好医院启动。吉利德今日也发布声明宣布正在配合中国的卫生部门开展一项随机、对照试验，以确定使用Remdesivir（瑞德西韦）治疗2019-nCoV感染者是否安全和有效。

在体外和动物模型中，Remdesivir（瑞德西韦）证实了对非典型性肺炎（SARS）和中东呼吸综合征（MERS）的病毒病原体均有活性，它们也属于冠状病毒，且与2019-nCoV在结构上非常相似。但将Remdesivir（瑞德西韦）紧急用于治疗埃博拉病毒感染者的临床数据也有限。

Remdesivir（瑞德西韦）尚未在任何国家获得批准上市，其安全性和有效性也未被证实。Remdesivir（瑞德西韦）是在研药物，没有针对2019-nCoV的数据。在没有任何已获批的治疗方案的情况下，治疗医生权衡了风险和获益后提出用药请求，在当地监管机构的支持下，吉利德提供了试验性药物Remdesivir（瑞德西韦），用于少数2019-nCoV感染者的急症治疗。

在研究中，国内外学者发表了多篇研究论文，具体但不保证完全罗列如下：

1. 瑞得西韦和磷酸氯喹能在体外有效抑制新型冠状病毒（2019-nCoV）

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.

Cell Research (2020) 0:1–3; https://doi.org/10.1038/s41422-020-0282-0

s41422-020-0282-0.pdf

2.2019-nCoV肺炎患者的感染和临床特征

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

The LancetIn press, corrected proofAvailable online 24 January 2020

Chaolin Huang, Yeming Wang, Xingwang Li, Lili Ren, Bin Cao

Published:January 24, 2020DOI:https://doi.org/10.1016/S0140-6736(20)30183-5

1-s2.0-S0140673620301835-main.pdf

3.美国确诊的第一例新型冠状病毒患者临床诊断及检测情况

First Case of 2019 Novel Coronavirus in the United States

Michelle L. Holshue, Chas DeBolt, Scott Lindquist, Kathy H. Lofy,John Wiesman, Hollianne Bruce,, Christopher Spitters, Keith Ericson,Sara Wilkerson, Ahmet Tural,, George Diaz,, Amanda Cohn,,

N Eng J Med.

10.1056@NEJMoa2001191.pdf

4.广谱抗病毒瑞德西韦（remdesivir）抑制由RNA依赖RNA聚合酶高度变异引起的人畜共患δ冠状病毒病研究

Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase

Brown, Ariane J.; Won, John J.; Graham, Rachel L.; ANTIVIRAL RESEARCH 169 UNSP 104541 SEP 2019

DOI: 10.1016/j.antiviral.2019.104541

1-s2.0-S0166354219300993-main.pdf

5.瑞德西韦（GS-5734）保护非洲绿猴面受尼帕病毒的感染

Remdesivir (GS-5734) protects African green monkeys from Nipah virus challenge

作者: Lo, Michael K.; Feldmann, Friederike; Gary, Joy M.; 等.

SCIENCE TRANSLATIONAL MEDICINE 卷: 11 期: 494 文献号: eaau9242 出版年: MAY 29 2019

nihms-421435.pdf

6.瑞德西韦对RNA依赖RNA聚合酶的埃博拉病毒的抑制机制研究

Mechanism of Inhibition of Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir

作者: Tchesnokov, Egor P.; Feng, Joy Y.; Porter, Danielle P.; 等.

VIRUSES-BASEL 卷: 11 期: 4 文献号: 326 出版年: APR 2019

tchesnokov2019.pdf

7. 对新型冠状病毒敏感的抗病毒药瑞德西韦（GS-5734）通过作用病毒RNA聚合酶和核糖核酸外切酶来实现病毒抑制的

Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease

作者: Agostini, Maria L.; Andres, Erica L.; Sims, Amy C.; 等.

MBIO 卷: 9 期: 2 文献号: e00221-18 出版年: MAR-APR 2018

mBio. 2018 Mar 6;9(2). pii: e00221-18. doi: 10.1128/mBio.00221-18.

agostini2018.pdf

8.药瑞德西韦（GS-5734）与复方洛匹那韦、利托那韦和β干扰素抗击中东呼吸综合症冠状病毒的疗效比较

Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV

Timothy P. Sheahan, Amy C. Sims[…]Ralph S. Baric

Nature Communications 11 , 1–14

s41467-019-13940-6.pdf

9.埃博拉病毒实验中最好的新抗体药ZMapp（报道）

New antibodies best ZMapp in Ebola trial

Nature Biotechnology 37 , 1105–1105

s41587-019-0284-y.pdf

10.作为广谱抗病毒靶点的胆固醇调节元件结合蛋白(SREBP)依赖性类脂细胞重编程研究

SREBP-dependent lipidomic reprogramming as a broad-spectrum antiviral target

Shuofeng Yuan, Hin Chu[…]Kwok-Yung Yuen

Nature Communications 10 , 1–15

s41467-018-08015-x.pdf

11. 显著提高埃博拉病毒感染者存活率的靶向治疗策略

Therapeutic strategies to target the Ebola virus life cycle

Thomas Hoenen, Allison Groseth & Heinz Feldmann

Nature Reviews Microbiology volume 17, pages593–606(2019)Cite this article

hoenen2019.pdf

12.埃博拉病毒在非人灵长类动物中的动态研究结果为病毒免疫和抗击研究提供了新视角

Ebola viral dynamics in nonhuman primates provides insights into virus immuno-pathogenesis and antiviral strategies

Vincent Madelain, Sylvain Baize[…]Jérémie Guedj

Nature Communications 9 , 1–11

s41467-018-06215-z.pdf

13.埃博拉病毒病治疗的随机对照试验

A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics

December 12, 2019

N Engl J Med 2019; 381:2293-2303

DOI: 10.1056/NEJMoa1910993

10.1056@NEJMoa1910993.pdf

14.埃博拉病毒病的单克隆抗体治疗(Editorial)

Monoclonal Antibody Therapy for Ebola Virus Disease List of authors.

Myron M. Levine, M.D., D.T.P.H.

N Engl J Med 2019; 381:2365-2366

DOI: 10.1056/NEJMe1915350

10.1056@NEJMe1915350.pdf

15.埃博拉疫情爆发促使实验性药物的研发（报道）

Ebola outbreak prompts experimental drug rollout.

Mullard, A. Nat Rev Drug Discov 17, 460 (2018).

https://doi.org/10.1038/nrd.2018.114

mullard2018.pdf

16.莫科制药领衔埃博拉疫苗研发（报道）

Merck vaccine heads Ebola countermeasures

Cormac Sheridan

Nature Biotechnology 36 , 563–565

nbt0718-563a.pdf

17.热性疾病药物研发进展和面临的挑战

Challenges and recent progress in drug discovery for tropical diseases

Manu De Rycker, Beatriz Baragaña[…]Ian H. Gilbert

Nature 559 , 498–506

s41586-018-0327-4.pdf

18.呼吸道病毒治疗学进展——第6届抗病毒会议报告

Advances in respiratory virus therapeutics – A meeting report from the 6th isirv Antiviral Group conference

Advances in respiratory virus therapeutics – A meeting report from the 6th isi.pdf

19.核苷类似物治疗冠状病毒感染

Nucleoside analogues for the treatment of coronavirus infections

Current Opinion in VirologyVolume 35April 2019Pages 57-62

Andrea J Pruijssers, Mark R Denison
1-s2.0-S187962571930001X-main.pdf

20.指导应对刚果民主共和国正在爆发的埃博拉病毒感染和特征系统发育和体外分析

Characterisation of infectious Ebola virus from the ongoing outbreak to guide response activities in the Democratic Republic of the Congo: a phylogenetic and in vitro analysis

The Lancet Infectious DiseasesVolume 19, Issue 9September 2019Pages 1023-1032

Laura K McMullan, Mike Flint, Ayan Chakrabarti, Lisa Guerrero, César Albariño

Characterisation of infectious Ebola virus from the ongoing outbreak to guide re.pdf

21. 交流、沟通和合作能战胜2019 年新型冠状病毒 (2019-nCoV) (Editorial)

Editorial | 3 February 2020

Communication, collaboration and cooperation can stop the 2019 coronavirus

Nature Medicine , 1–1

s41591-020-0775-x.pdf

22.新型核苷类似物治疗出血热病毒感染

New Nucleoside Analogues for the Treatment of Hemorrhagic Fever Virus Infections

Prof. Dr. Erik De Clercq

First published:07 August 2019

https://doi.org/10.1002/asia.201900841

asia.201900841.pdf

23.埃博拉病毒感染的疾病

Ebola virus disease.

Beeching, N. J., Fenech, M., & Houlihan, C. F. (2014).

BMJ, 349(dec10 28), g7348–g7348.doi:10.1136/bmj.g7348

beeching2014.pdf

24.埃博拉病毒感染和治疗期间的宿主动力学建模研究

Modeling Challenges of Ebola Virus–Host Dynamics during Infection and Treatment
DS Chertow, L Shekhtman, Y Lurie, RT Davey, T Heller… - Viruses, 2020

https://doi.org/10.5582/bst.2020.01020

chertow2020.pdf

25.战胜当前刚果民主共和国东部埃博勒病毒病感染的一种潜在方案：基于模拟计算视角

A potential roadmap to overcome the current eastern DRC Ebol avirus disease outbreak: From a computational perspective

Gaston K. Mazandu , Victoria Nembaware , Nicholas E. Thomford ,Christian Bope , Ousmane Ly , Emile R. Chimusa ,Ambroise Wonkam

1-s2.0-S246822762030020X-main.pdf

26.新型冠状病毒（2019-nCoV）药物治疗方案

Drug treatment options for the 2019-new coronavirus (2019-nCoV)
Hongzhou L
BioScience Trends

https://doi.org/10.5582/bst.2020.01020

advpub_2020.01020.pdf

27.核苷酸类似物抑制病毒聚合酶治疗新型冠状病毒（bioRxiv）

Nucleotide Analogues as Inhibitors of Viral Polymerases

Jingyue Jua, Shiv Kumar, Xiaoxu Li, Steffen Jockuscha, and James J. Russo
http://dx.doi.org/10.1101/2020.01.30.927574

2020.01.30.927574v1.full.pdf

28. SARS病毒、MERS 中东呼吸综合症冠状病毒和新型冠状病毒（2019-nCoV）人畜共患病冠状病毒的出现对人类的威胁

Emerging threats from zoonotic coronaviruses-from SARS and MERS to 2019-nCoV

Journal of Microbiology, Immunology and InfectionIn press, journal pre-proofAvailable online 4 February 2020

Ping-Ing Lee, Po-Ren Hsueh

1-s2.0-S1684118220300116-main.pdf

29.埃博勒病毒库新技术

New Tools in the Ebola Arsenal.

Damon, I. K., Rollin, P. E., Choi, M. J., Arthur, R. R., & Redfield, R. R. (2018).

New England Journal of Medicine. doi:10.1056/nejmp1811751

damon2018.pdf

30.2019 新型冠状病毒抗病毒治疗有药可期

Potential antiviral therapeutics for 2019 Novel Coronavirus

Zhonghua Jie He He Hu Xi Za Zhi. 2020 Feb 5;43(0):E002.

doi: 10.3760/cma.j.issn.1001-0939.2020.0002.

1001-0939-43-0002s.pdf

31.以史为镜,开创未来：2019 新型冠状病毒引起的严重急性呼吸道感染可能的紧急防治选择

Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019-nCoV.

Liu W, Morse JS, Lalonde T, Xu S.

Chembiochem. 2020 Feb 5. doi: 10.1002/cbic.202000047. [Epub ahead of print]

PMID: 32022370

cbic.202000047.pdf

32.刚果民主共和国复发性埃博拉病毒病：新进展和挑战

Recurrent Ebolavirus disease in the Democratic Republic of Congo: update and challenges.

Inungu J, Iheduru-Anderson K, Odio OJ.

AIMS Public Health. 2019 Nov 20;6(4):502-513. doi: 10.3934/publichealth.2019.4.502. eCollection 2019.

publichealth-06-04-502.pdf

33.关注公共健康

Public health round-up.

Bull World Health Organ. 2019 Jan 1;97(1):4-5. doi: 10.2471/BLT.19.010119.

BLT.19.010119.pdf

34.小分子化合物瑞德西韦（GS-5734）强效治疗猕猴埃博拉病毒研究

Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys.

Warren TK, Jordan R, Lo MK, Ray AS, Mackman RL, Soloveva V, Siegel D, Perron M, Bannister R, Hui HC, Larson N, Strickley R, Wells J, Stuthman KS, Van Tongeren SA, Garza NL, Donnelly G, Shurtleff AC, Retterer CJ, Gharaibeh D, Zamani R, Kenny T, Eaton BP, Grimes E, Welch LS, Gomba L, Wilhelmsen CL, Nichols DK, Nuss JE, Nagle ER, Kugelman JR, Palacios G, Doerffler E, Neville S, Carra E, Clarke MO, Zhang L, Lew W, Ross B, Wang Q, Chun K, Wolfe L, Babusis D, Park Y, Stray KM, Trancheva I, Feng JY, Barauskas O, Xu Y, Wong P, Braun MR, Flint M, McMullan LK, Chen SS, Fearns R, Swaminathan S, Mayers DL, Spiropoulou CF, Lee WA, Nichol ST, Cihlar T, Bavari S.

Nature. 2016 Mar 17;531(7594):381-5. doi: 10.1038/nature17180. Epub 2016 Mar 2. Erratum in: ACS Chem Biol. 2016 May 20;11(5):1463.

PMID: 26934220 Free PMC Article

nihms756219.pdf

35.一例埃博拉病毒复发感染致脑膜炎的病例研究报道

Late Ebola virus relapse causing meningoencephalitis: a case report.

Jacobs M, Rodger A, Bell DJ, Bhagani S, Cropley I, Filipe A, Gifford RJ, Hopkins S, Hughes J, Jabeen F, Johannessen I, Karageorgopoulos D, Lackenby A, Lester R, Liu RS, MacConnachie A, Mahungu T, Martin D, Marshall N, Mepham S, Orton R, Palmarini M, Patel M, Perry C, Peters SE, Porter D, Ritchie D, Ritchie ND, Seaton RA, Sreenu VB, Templeton K, Warren S, Wilkie GS, Zambon M, Gopal R, Thomson EC.

Lancet. 2016 Jul 30;388(10043):498-503. doi: 10.1016/S0140-6736(16)30386-5. Epub 2016 May 18.

1-s2.0-S0140673616303865-main.pdf

36.瑞德西韦（GS-5734）治愈第一例感染埃博拉病毒的新生儿

First Newborn Baby to Receive Experimental Therapies Survives Ebola Virus Disease.

Dörnemann J, Burzio C, Ronsse A, Sprecher A, De Clerck H, Van Herp M, Kolié MC, Yosifiva V, Caluwaerts S, McElroy AK, Antierens A.

J Infect Dis. 2017 Jan 15;215(2):171-174. doi: 10.1093/infdis/jiw493.

jiw493.pdf

37.发现和合成一种治疗埃博拉病毒和新病毒的氨基磷酸酯药物（吡咯[2,1-f][三嗪-4-氨基]腺嘌呤 C-核苷）瑞德西韦（GS-5734）

Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses.

Siegel D, Hui HC, Doerffler E, Clarke MO, Chun K, Zhang L, Neville S, Carra E, Lew W, Ross B, Wang Q, Wolfe L, Jordan R, Soloveva V, Knox J, Perry J, Perron M, Stray KM, Barauskas O, Feng JY, Xu Y, Lee G, Rheingold AL, Ray AS, Bannister R, Strickley R, Swaminathan S, Lee WA, Bavari S, Cihlar T, Lo MK, Warren TK, Mackman RL.

J Med Chem. 2017 Mar 9;60(5):1648-1661. doi: 10.1021/acs.jmedchem.6b01594. Epub 2017 Feb 14.

siegel2017.pdf

38.瑞德西韦（GS-5734）和亲本核苷类似物抑制丝状病毒、病毒属、副粘病毒研究

GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses.

Lo MK, Jordan R, Arvey A, Sudhamsu J, Shrivastava-Ranjan P, Hotard AL, Flint M, McMullan LK, Siegel D, Clarke MO, Mackman RL, Hui HC, Perron M, Ray AS, Cihlar T, Nichol ST, Spiropoulou CF.

Sci Rep. 2017 Mar 6;7:43395. doi: 10.1038/srep43395.

39.埃博拉病毒新疗法（EDITORIALS）

New treatments for Ebola virus disease.

Lucey DR.

BMJ. 2019 Sep 6;366:l5371. doi: 10.1136/bmj.l5371. No abstract available.

PMID: 31492688

lucey2019.pdf

40.埃博拉在研的广谱抗病毒药瑞德西韦（GS-5734）还可抑制人畜共患传染病源冠状病毒

Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses.

Sheahan TP, Sims AC, Graham RL, Menachery VD, Gralinski LE, Case JB, Leist SR, Pyrc K, Feng JY, Trantcheva I, Bannister R, Park Y, Babusis D, Clarke MO, Mackman RL, Spahn JE, Palmiotti CA, Siegel D, Ray AS, Cihlar T, Jordan R, Denison MR, Baric RS.

Sci Transl Med. 2017 Jun 28;9(396). pii: eaal3653. doi: 10.1126/scitranslmed.aal3653.

Sheahan-2017-Broad-spectrum-antiviral-gs--inhibi.pdf

41.埃博拉病毒感染者将被治愈？

Will There Be a Cure for Ebola?

Cardile AP, Warren TK, Martins KA, Reisler RB, Bavari S.

Annu Rev Pharmacol Toxicol. 2017 Jan 6;57:329-348. doi: 10.1146/annurev-pharmtox-010716-105055. Epub 2016 Dec 7. Review.

cardile2017.pdf

42.抗埃博拉病毒药物发现研究

Discovering Drugs for the Treatment of Ebola Virus.

Bixler SL, Duplantier AJ, Bavari S.

Curr Treat Options Infect Dis. 2017;9(3):299-317. doi: 10.1007/s40506-017-0130-z. Epub 2017 Aug 4. Review.

PMID: 28890666 Free PMC Article

40506_2017_Article_130.pdf

43.通过一种副粘病毒聚合酶实现对RNA复制的启动、增长和终止调控

Initiation, extension, and termination of RNA synthesis by a paramyxovirus polymerase.

Jordan PC, Liu C, Raynaud P, Lo MK, Spiropoulou CF, Symons JA, Beigelman L, Deval J.

PLoS Pathog. 2018 Feb 9;14(2):e1006889. doi: 10.1371/journal.ppat.1006889. eCollection 2018 Feb.

PMID: 29425244 Free PMC Article

ppat.1006889.pdf

44.埃博拉病毒治疗进入随机对照试验阶段

Randomised controlled trial begins for Ebola therapeutics.

Nakkazi E.

Lancet. 2018 Dec 1;392(10162):2338. doi: 10.1016/S0140-6736(18)33011-3. No abstract available.

PMID: 30527603

Nakkazi-2018-Randomised-controlled-trial-begins-.pdf

45.治疗埃博拉疫情药物实验准备就绪（报道）

Experimental drugs poised for use in Ebola outbreak.

Check Hayden E.

Nature. 2018 May;557(7706):475-476. doi: 10.1038/d41586-018-05205-x. No abstract available.

PMID: 29789732‘’

Check-hayden-2018-Experimental-drugs-poised-for-use-i.pdf

46.利用仓鼠模式研究流感治疗药物法匹拉韦Favipiravir (T-705)防治Nipah病毒感染

Favipiravir (T-705) protects against Nipah virus infection in the hamster model

BE Dawes, B Kalveram, T Ikegami, T Juelich

SCIENTIFIC RePorts | (2018) 8:7604 | DOI:10.1038/s41598-018-25780-3

s41598-018-25780-3.pdf

47.核苷类似物GS-441524显著抑制猫传染性腹膜炎冠状病毒在组培和实验猫感染中研究

The nucleoside analog GS-441524 strongly inhibits feline infectious peritonitis (FIP) virus in tissue culture and experimental cat infection studies

BG Murphy, M Perron, E Murakami, K Bauer

Veterinary Microbiology Volume 219, June 2018, Pages 226-233

The nucleoside analog GS-441524 strongly inhibits feline infectious peritonitis .pdf

48.新型核苷酸类似物抑制丝状病毒新疗法研究

Flex-nucleoside analogues–novel therapeutics against filoviruses

MK Yates, MR Raje, P Chatterjee

Bioorganic & Medicinal Chemistry Letters Volume 27, Issue 12, 15 June 2017, Pages 2800-2802

yates2017.pdf

49.ProTide前药技术的繁荣

The ProTides Boom

Youcef Mehellou

ChemMedChem 2016, 11, 1114 – 1116

DOI: 10.1002/cmdc.201600156

mehellou2016.pdf

50.磷酸核苷和磷酸盐前驱要获准临床实验观察

Nucleoside Phosphate and Phosphonate Prodrug Clinical Candidates Miniperspective

Peter J. Thornton Hachemi Kadri Ageo Miccoli Youcef Mehellou

J. Med. Chem. 2016, 59, 23, 10400-10410

Publication Date:August 25, 2016

https://doi.org/10.1021/acs.jmedchem.6b00523

thornton2016.pdf

51.通过核糖、2′‐脱氧核糖和2′,3′‐二去氧核糖体化学合成吡咯[2,1-f][1,2,4]三嗪 C-核苷酸及生物学评价

Synthesis and Biological Evaluation of Pyrrolo[2,1‐f][1,2,4]triazine C‐Nucleosides with a Ribose, 2′‐Deoxyribose, and 2′,3′‐Dideoxyribose Sugar Moiety

Li, Q., Lescrinier, E., Groaz, E., Persoons, L., Daelemans, D., Herdewijn, P., & De Jonghe, S. (2017). ChemMedChem, 13(1), 97–104.

doi:10.1002/cmdc.201700657

li2017.pdf

52.In situ Oxidation and Self-Assembly Synthesis of Dumbbell-Like α-Fe2O3/Ag/AgX(X = Cl, Br, I) Heterostructures with Enhanced Photocatalytic Properties.

Lingling Sun, Wei Wu, Qingyong Tian, Mei Lei, Jun Liu, Xiangheng Xiao, Xudong Zheng, Feng Ren, Changzhong Jiang

ACS Sustainable Chemistry& Engineering, 2016, 4, 1521-1530

sun2016.pdf

53. 医药化学合成C-核苷酸类似物研究进展

Recent advances in synthetic approaches for medicinal chemistry of C-nucleosides

Kartik Temburnikar and Katherine L. Seley-Radtke

Beilstein J. Org. Chem. 2018, 14, 772–785. doi:10.3762/bjoc.14.65

1860-5397-14-65.pdf

54.抗埃博拉病毒早期临床用药研究进展

The early clinical development of Ebola virus treatments

Steven B. Bradfute

Pages 1-4 | Received 22 Aug 2016, Accepted 10 Nov 2016, Accepted author version posted online: 12 Nov 2016, Published online: 21 Nov 2016

https://doi.org/10.1080/13543784.2017.1260545

The early clinical development of Ebola virus treatments.pdf

55.埃博拉病毒病：暴露后的更新预防治疗

Ebola virus disease: an update on post-exposure prophylaxis

William A Fischer , Pauline Vetter , Daniel G Bausch

The Lancet Infectious Diseases

Volume 18, Issue 6, June 2018, Pages e183-e192

Ebola virus disease_ an update on post-exposure prophylaxis.pdf

56.新的抗呼吸道病毒和单负义链RNA病毒的病毒类似物抑制RNA 聚合酶研究

New antiviral approaches for respiratory syncytial virus and other mononegaviruses: Inhibiting the RNA polymerase

Rache Fearns, Jerome Deval

Antiviral Research 134 (2016) 63e76

http://dx.doi.org/10.1016/j.antiviral.2016.08.006

New antiviral approaches for respiratory syncytial virus and other mononegavirus.pdf

57.呼吸道合胞病毒Respiratory Syncytial Virus (RSV):创新疗法展望

Respiratory syncytial virus: prospects for new and emerging therapeutics

Patricia A. Jorquera Icon & Ralph A. Tripp

Expert Review of Respiratory Medicine

Volume 11, 2017 - Issue 8 Pages 609-615

https://doi.org/10.1080/17476348.2017.1338567

jorquera2017 (1).pdf

58.多价糖基纳米结构化合物抑制埃博拉病毒感染研究

Multivalent Glycosylated Nanostructures To Inhibit Ebola Virus Infection

Beatriz M. Illescas Javier Rojo OrcidRafael Delgado Nazario Martín

J. Am. Chem. Soc. 2017, 139, 17, 6018-6025

https://doi.org/10.1021/jacs.7b01683

illescas2017.pdf

59.埃博拉病毒感染：抗病毒药物在人体作用实验中的药代动力学和药效学特性研究综述

Ebola Virus Infection: Review of the Pharmacokinetic and Pharmacodynamic Properties of Drugs Considered for Testing in Human Efficacy Trials

Vincent Madelain, Thi Huyen Tram Nguyen, Anaelle Olivo, Xavier de Lamballerie, Jérémie Guedj, Anne-Marie Taburet & France Mentré

Clinical Pharmacokinetics volume 55, pages907–923(2016)

madelain2016.pdf

60.核苷酸药物前体瑞德西韦（GS-5734）是广谱丝状病毒抑制剂，在治疗埃博拉病毒感染的非人类灵长类动物方面疗效显著

Nucleotide Prodrug GS-5734 Is a Broad-Spectrum Filovirus Inhibitor That Provides Complete Therapeutic Protection Against the Development of Ebola Virus Disease (EVD) in Infected Non-human Primates

Travis Warren, Robert Jordan, Michale Lo, Veronica Soloveva, Adrian Ray, Roy Bannister, Richard Mackman, Michel Perron, Kirsten Stray, Joy Feng

Open Forum Infectious Diseases, Volume 2, Issue suppl_1, December 2015, LB-2, https://doi.org/10.1093/ofid/ofv130.02

warren2015.pdf

61.核苷和非核苷类药物抗病毒近五年研究进展

Advanced Prodrug Strategies in Nucleoside and Non-Nucleoside Antiviral Agents: A Review of the Recent Five Years

Sinokrot, H.; Smerat, T.; Najjar, A.; Karaman, R.

Molecules 2017, 22(10), 1736; https://doi.org/10.3390/molecules22101736

molecules-22-01736.pdf

62.重组RNA依赖性RNA聚合酶抗埃博拉病毒研究

Recombinant RNA-Dependent RNA Polymerase Complex of Ebola Virus

Egor P. Tchesnokov, Parisa Raeisimakiani, Marianne Ngure, David Marchant1,&

Matthias Götte